Norovirus Market

Market Overview:

The 7 major norovirus markets reached a value of USD 140.07 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 545.02 Million by ​2035​, exhibiting a growth rate (CAGR) of 31.1% during ​2025-2035​.

The norovirus market has been comprehensively analyzed in IMARC's new report titled "Norovirus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Norovirus is a highly contagious virus that causes acute gastroenteritis, an inflammation of the stomach and intestines. It can be transmitted through contaminated food or water, direct contact with an infected person, or touching contaminated surfaces. The symptoms of norovirus typically begin 12 to 48 hours after exposure and include sudden onset of nausea, vomiting, watery diarrhea, stomach cramps, and sometimes low-grade fever, headache, and body aches. While symptoms usually resolve within 1 to 3 days in healthy individuals, the condition can cause severe dehydration, especially in young children, the elderly, and immunocompromised individuals. Diagnosis of norovirus involves a detailed medical history review, clinical assessment, and laboratory investigations. The healthcare providers may also recommend stool tests to confirm the diagnosis, especially in cases of outbreaks or when symptoms are severe or prolonged. Furthermore, immunochromatographic tests might be performed to identify both genogroups I (GI) and II (GII) noroviruses, which are common causes of gastroenteritis. These tests are useful for rapid screening, especially in cases where more complex methods like are not readily available.

The escalating cases of viral diseases, where the virus typically enters through the mouth after consuming contaminated food, water, or via hand-to-mouth contact with infected surfaces or people, are primarily driving the norovirus market. In addition to this, the inflating utilization of anti-diarrheal agents, such as loperamide and bismuth subsalicylate to relieve symptoms of the ailment, is also creating a positive outlook for the market. Moreover, the widespread adoption of oral rehydration therapy, since it helps to maintain fluid and electrolyte balance, thereby preventing dehydration in mild to moderate cases, is further bolstering the market growth. Apart from this, the rising popularity of passive immunotherapy that involves using pre-made antibodies to fight the infection, rather than stimulating the body's immune response, is acting as another significant growth-inducing factor. This can be achieved through various methods, including the administration of monoclonal antibodies, nanobodies, or oral human immunoglobulin. Additionally, the emerging application of microfluidics for studying and detecting norovirus even in a reduced sample volume, is expected to drive the norovirus market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the norovirus market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for norovirus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the norovirus market in any manner.

Recent Developments:

• In May 2025, Vaxart disclosed that the full results of a Phase 2b challenge study of its first-generation oral pill norovirus vaccine candidate (NCT05212168) had been published in Science Translational Medicine. According to the complete data, the trial met five of its six key objectives and proved the vaccine candidate's safety, effectiveness, and immunogenicity, which was consistent with preliminary data announced in September 2023.
• In September 2024, stated that the Nova 301 trial, critical Phase 3 randomized clinical research testing the effectiveness, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403, had dosed its first participant in the United States.
• In July 2024, HilleVax released the NEST-IN1 topline data results. NEST-IN1 is a Phase 2b, randomized, double-blind, placebo-controlled study being conducted in the United States and Latin America that will assess the efficacy, safety, and immunogenicity of HIL-214 in infants aged around 5 months at the time of initial immunization.

Drugs:

Norovirus GI.1/GII.4 bivalent VLP vaccine by Hillevax uses virus-like particles (VLPs) that mimic the structure of norovirus without containing viral genetic material. These VLPs stimulate the immune system to produce neutralizing antibodies against both GI.1 and GII.4 norovirus strains. This immune response prepares the body to recognize and block actual norovirus infections, reducing infection risk and severity without causing disease.

VXA-G1.1-NN, an oral norovirus vaccine developed by Vaxart, uses a non-replicating adenovirus vector to express the norovirus G1.1 VP1 antigen and a double-stranded RNA adjuvant. The vaccine is designed to bypass the stomach and release its contents in the small intestine, where it triggers an immune response by stimulating host cells to express the VP1 antigen. This expression leads to the production of antibodies, including IgA in saliva and fecal samples, and the generation of T cell responses both systemically and mucosally.

mRNA-1403 is a trivalent mRNA-based vaccine designed to protect against norovirus, targeting the GII.4, GI.3, and GII.3 genotypes. Upon intramuscular injection, the lipid nanoparticle (LNP)-encapsulated mRNA is delivered into host cells, instructing them to produce the major capsid protein 1 (VP1) of these norovirus strains. This VP1 protein self-assembles into virus-like particles (VLPs), which are recognized by the immune system as foreign. The immune response includes the production of histo-blood group antigen (HBGA)-blocking antibodies that can neutralize the virus, preventing infection and reducing the severity of disease upon exposure.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the norovirus market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the norovirus market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current norovirus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the norovirus market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the norovirus across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the norovirus across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (​2019-2035​) of norovirus across the seven major markets?
• What is the number of incident cases (​2019-2035​) of norovirus by age across the seven major markets?
• What is the number of incident cases (​2019-2035​) of norovirus by gender across the seven major markets?
• What is the number of incident cases (​2019-2035​) of norovirus by type across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with norovirus across the seven major markets?
• What is the size of the norovirus patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend norovirus of?
• What will be the growth rate of patients across the seven major markets?

Norovirus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for norovirus drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the norovirus market?
• What are the key regulatory events related to the norovirus market?
• What is the structure of clinical trial landscape by status related to the norovirus market?
• What is the structure of clinical trial landscape by phase related to the norovirus market?
• What is the structure of clinical trial landscape by route of administration related to the norovirus market?